Acelyrin — Merger or Acquisition (March 2025)
7 slides from Acelyrin's merger presentation, Mar 6, 2025
Slide 1: Creating Substantial Shareholder Value Through the Advancement of Immunology Treatments
Exhibit 99.1 Creating Substantial Shareholder Value Through the Advancement of Immunology Treatments March 2025
Slide 2: Disclaimer
Disclaimer Financial Disclaimer The audited consolidated financial statements of Alumis Inc. (“Alumis”) and ACELYRIN, Inc. (“ACELYRIN”) for the year ended December 31, 2024 are not yet available. Accordingly, the information presented herein regarding cash, cash equivalents and marketable securities
Slide 3: Transaction Highlights
Transaction Highlights › All Stock Merger Consideration › ACELYRIN stockholders to receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock owned Pro Forma › Alumis stockholders to own approximately 55% of the combined company 1 Ownership › ACELYRIN stockholders to own ap
Slide 4: Compelling Strategic Rationale
Compelling Strategic Rationale 1 Creates a leading late-stage clinical biopharma company in immune-mediated diseases Differentiated and late-stage portfolio for validated targets in large, well-established 2 multi-billion dollar markets 3 Multiple, meaningful near-term catalysts Led by a deep and ex
Slide 5: Comprehensive Process Resulting in Transaction with Alumis
Comprehensive Process Resulting in Transaction with Alumis Board undertook an extensive process that began in 2Q 2024 and resulted in the proposed merger with Alumis This process included interactions with ~25 potential counterparties and the exploration of a wide variety of transactions The transac
Slide 6: The ACELYRIN Board Believes that the Transaction Provides Potential for Substantial Value Accretion
The ACELYRIN Board Believes that the Transaction Provides Potential for Substantial Value Accretion › Intrinsic value per share represents substantial upside to Acelyrin’s current trading price › Combination with Alumis is value accretive to ACELYRIN stockholders via synergies, scale and shared owne
Slide 7: Annex I – Certain Disclosures and Other Considerations
Annex I – Certain Disclosures and Other Considerations The February 6, 2025 Presentation was necessarily based on economic, business, capital markets and other conditions, and the information made available to Guggenheim Securities as of the date of such presentation. Guggenheim Securities has no re